Early user data and demonstrations at the Association for Molecular Pathology show two instrument moves that could accelerate cancer genomic workflows. Roche previewed Axelios 1, a sequencing‑by‑expansion nanopore platform, with tumor‑normal concordance comparable to Illumina and fast throughput for cancer genomics and ctDNA applications. Roche highlighted automated library prep and concurrent variant‑and‑methylation detection as platform differentiators. Thermo Fisher presented performance data for its Oncomine Comprehensive Assay Plus on the automated Ion Torrent Genexus system, claiming next‑day comprehensive genomic profiling with low hands‑on time and high success rates for challenging samples. Thermo emphasized amplicon‑based workflows that reduce tissue input and sequencing failures. Laboratories evaluating both platforms noted tradeoffs—speed, automation, and sample requirements versus established validation pathways—and flagged bioinformatics and regulatory alignment as adoption hurdles. These platform pushes could compress CGP turnaround times and expand routine clinical use if analytical and clinical validation keep pace.